WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics, Inc., a biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective anti-cancer medicines, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 9th Annual Biotech Showcase. Mr. Fromkin will discuss the Company’s Pentarin miniaturized drug conjugate platform, including PEN-221, which is currently in clinical evaluation for the treatment of patients with neuroendocrine and small cell lung cancers. The presentation will take place on Monday, January 9, 2017 at 10:00 a.m. Pacific Time in San Francisco, CA.
About Pentarins™
Tarveda is developing Pentarins, potent and
selective miniaturized drug conjugates with high affinity for specific
cell surface and intracellular targets. Pentarins are engineered to bind
to their tumor cell targets and provide sustained release of their
potent therapeutic payloads deep into solid tumor tissue. Comprised of a
targeting ligand conjugated to a potent cell-killing agent through a
chemical linker, Pentarins are designed to overcome the deficits of both
larger antibody drug conjugates and small molecules that limit their
therapeutic effectiveness against solid tumors. Together, the components
of Tarveda’s Pentarins have distinct, yet synergistic, anticancer
attributes: the small size of Pentarins allows for effective penetration
and distribution into the tumor tissue, the ligand’s targeting ability
allows for specific binding and retention in tumor cells, and the
chemical linker is tuned to optimize the release of the potent,
cell-killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc.
discovers and develops Pentarins™, a new class of potent and selective
miniaturized drug conjugates with enhanced targeting capabilities for
the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug
candidate, PEN-221, is a miniaturized drug conjugate that targets the
somatostatin receptor 2 (SSTR2) for treatment of patients with
neuroendocrine and small cell lung cancers. PEN-221 comprises a highly
selective peptide that targets SSTR2 linked to the potent cytotoxic DM1
through a cleavable linker. Tarveda is also advancing its HSP90 drug
conjugate platform with lead drug candidate PEN-866, which is a
miniaturized drug conjugate that comprises a small molecule HSP90
targeting ligand conjugated to SN-38, the highly-potent, active
metabolite of irinotecan. Tarveda’s strategy includes developing its own
proprietary Pentarins as well as applying the Pentarin platform to
enhance the effectiveness of the targeting moieties and novel payloads
of its pharmaceutical collaborators. www.tarveda.com
